Clinical Trial: A Phase I, Multi-center, Dose Escalation, Double-blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the BMI2012 Against COVID-19 Variant in Healthy Adults Between 19 and 55 Years of Age

U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07791186) titled 'A Phase I, Multi-center, Dose Escalation, Double-blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the BMI2012 Against COVID-19 Variant in Healthy Adults Between 19 and 55 Years of Age' on Aug. 25.

Brief Summary: This Phase 1, multi-center, randomized, double-blind, placebo-controlled, dose-escalation study evaluates the safety, tolerability, and immunogenicity of BMI2012, a self-amplifying RNA vaccine candidate targeting the SARS-CoV-2 Omicron JN .1 variant, in healthy adults aged 19 to 55 years.

Participants will be enrolled sequentially into three ascending-dose cohorts and r...